BioCentury
ARTICLE | Finance

Clear path to POC

ClearPath leverages Symphony experience into Astellas vaccines deal

January 20, 2014 8:00 AM UTC

A history of managing single asset product development companies helped ClearPath Development Co.secure a partnership with Astellas Pharma Inc. (Tokyo:4502) to manage a portfolio of asset-centric companies focused on vaccines for infectious diseases.

According to ClearPath Chairman Chuck Finn, parent company RRD International LLC had 10 years of experience managing product development companies established by a $300 million Symphony Capital fund...